| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2026 , Vol 64 , Num 2
Serum neprilysin levels in acromegalic patients with and without diabetes mellitus
1 University of Mustansiriyah, College of Medicine, Department of Clinical Biochemistry, Baghdad, Iraq2 Mustansiriyah University, National Diabetes Center, Baghdad, Iraq
DOI : 10.23893/1307-2080.APS6408 Viewed : 910 - Downloaded : 459 Neprilysin is a zinc-dependent membrane metallopeptidase that degrades various bioactive peptides which have been linked to disorders such as obesity and type 2 diabetes mellitus. Acromegaly is characterized by excess growth hormone and insulin resistance; however, neprilysin"s involvement in acromegaly, especially in relation to diabetes, remains unclear. The study aimed to evaluate serum neprilysin levels in acromegalic patients with and without diabetes mellitus and to investigate their associations with glycemic and lipid metabolic markers in a cross-sectional study recruited from the National Diabetes Center (Baghdad, Iraq) between November 2024 and March 2025. Serum neprilysin was measured by ELISA, and standard biochemical tests (GH, IGF-1, glycemic indices, and lipid profile parameters) were performed to assess relevant hormones and metabolic parameters. Acromegalic patients had significantly higher GH and IGF-1 levels and worse glycemic and lipid profiles than controls (p<0.001). However, NEP levels (~110?130 pg/mL) did not differ significantly between the groups (p=0.316). Acromegalic group without diabetes showed a numerically higher NEP level than controls and acromegalic group with diabetes but this difference was not statistically significant. NEP showed significant weak inverse correlations with total cholesterol (r = -0.146, p=0.029), triglycerides (r = -0.199, p=0.008), and VLDL (r = -0.163, p=0.030), but no significant correlation with fasting glucose, HbA1c, GH, or IGF-1. In conclusion, these findings suggest that NEP is not a useful biomarker of diabetes risk or disease activity in acromegaly. Keywords : neprilysin, acromegaly, diabetes mellitus, growth hormone, IGF-1